Abstract
Background: There are multiple case reports in the literature describing an association between fingolimod and cutaneous neoplasms. Objective: Investigate and report a case of a primary mediastinal large B-cell lymphoma in a patient on fingolimod for Relapsing-Remitting Multiple Sclerosis (RRMS). Methods: Case Report. Results: The patient developed a primary mediastinal large B-cell lymphoma after seven years of treatment with fingolimod. The patient is currently in complete remission after cessation of treatment, surgical resection, chemotherapy, and radiation therapy. Conclusion: This case report highlights the first primary mediastinal large B-cell lymphoma associated with fingolimod treatment. It should be considered a rare, but potential adverse effect of fingolimod.
Original language | English (US) |
---|---|
Article number | 102776 |
Journal | Multiple Sclerosis and Related Disorders |
Volume | 49 |
DOIs | |
State | Published - Apr 2021 |
Keywords
- CD30
- Fingolimod
- Lymphoma
- Multiple sclerosis
- Primary mediastinal large B-cell lymphoma
ASJC Scopus subject areas
- Neurology
- Clinical Neurology